What Is Tirzepatide? A Complete Guide to the Dual-Action GLP-1/GIP Medication
Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist developed by Eli Lilly. Learn how this groundbreaking medication works, what it's approved for, and why it's changing the landscape of obesity and diabetes treatment.
Tirzepatide is a revolutionary medication that represents a paradigm shift in the treatment of type 2 diabetes and obesity. Developed by Eli Lilly and Company, it is the first medication to activate both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors simultaneously.
How Tirzepatide Works
Unlike traditional GLP-1 receptor agonists that target only one incretin pathway, tirzepatide works on two key hormonal pathways:
GIP (Glucose-Dependent Insulinotropic Polypeptide): This hormone is released from the gut after eating and enhances insulin secretion. It also plays a role in fat metabolism and energy balance.
GLP-1 (Glucagon-Like Peptide-1): This hormone slows gastric emptying, reduces appetite, and promotes insulin secretion while suppressing glucagon release.
By activating both receptors, tirzepatide produces more potent effects on blood sugar control and weight loss than medications targeting only one pathway.
FDA Approvals
Tirzepatide has received two major FDA approvals:
- Mounjaro® (May 2022): Approved for the treatment of type 2 diabetes mellitus as an adjunct to diet and exercise.
- Zepbound® (November 2023): Approved for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.
Mechanism of Action in Detail
Tirzepatide is a 39-amino acid synthetic peptide that is administered as a once-weekly subcutaneous injection. Its molecular structure is based on the GIP sequence, with modifications that allow it to also activate the GLP-1 receptor.
The dual receptor activation leads to:
- Enhanced insulin secretion in a glucose-dependent manner
- Reduced glucagon secretion when blood sugar is high
- Slowed gastric emptying, promoting feelings of fullness
- Reduced appetite through central nervous system effects
- Improved insulin sensitivity in peripheral tissues
- Enhanced fat metabolism and energy expenditure
Who Can Take Tirzepatide?
Tirzepatide may be appropriate for adults who:
- Have type 2 diabetes and need better glycemic control
- Have a BMI of 30 or greater (obesity)
- Have a BMI of 27 or greater with at least one weight-related condition such as hypertension, dyslipidemia, cardiovascular disease, obstructive sleep apnea, or type 2 diabetes
Important Considerations
Tirzepatide is not recommended for:
- People with a personal or family history of medullary thyroid carcinoma
- Patients with Multiple Endocrine Neoplasia syndrome type 2
- People with type 1 diabetes
- As a first-line therapy for type 2 diabetes before metformin
Always consult with a healthcare provider to determine if tirzepatide is appropriate for your individual situation.